Phase 1Status unknown

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cell for HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Sponsor
Corregene Biotechnology Co., Ltd (Industry)
Enrollment
12 planned
Conditions
Cervical Cancer; Anal Cancer; Head and Neck Cancers
Interventions
Fludarabine + Cyclophosphamide; Interleukin-2; CRTE7A2-01 TCR-T Cell
Ages
adults, older adults
Registry
NCT05122221

Full record on ClinicalTrials.gov

From the registry

A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D.

Primary outcomes

  • MTD
  • DLT
  • RP2D
  • Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).

History

  1. Study completion

  2. Primary completion

  3. Started

  4. Last registry update

  5. Registered